TREACE MEDICAL CONCEPTS ($NASDAQ:TMCI) reported their earnings for FY2023 Q2, which concluded on June 30 2023, on August 8 2023. Their total revenue rose by 40.0% from the same quarter the previous year, totaling USD 42.0 million. Net income was reported at USD -12.3 million, which is an improvement from the -17.2 million reported in FY2022 Q2.
The company reported that its stock opened at $20.7 and closed at $20.1, resulting in a 2.9% decrease from the prior closing price of $20.7. This decrease was attributed to gains in Q2, which did not meet Wall Street expectations. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for TMCI. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for TMCI. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for TMCI. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for TMCI are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – TMCI Intrinsic Stock Value
At GoodWhale, we’ve conducted an analysis of TREACE MEDICAL CONCEPTS’ fundamentals. Our proprietary Valuation Line has estimated that the fair value of TREACE MEDICAL CONCEPTS’ stock is around $29.8. However, currently the stock is being traded at only $20.1, which means the stock is undervalued by 32.5%. We believe this presents significant investment opportunity for investors in the short-term. More…
Risk Rating Analysis
Star Chart Analysis
The company has a strong product portfolio and a wide geographical presence. The company is facing stiff competition from its rivals Pace Medical Inc, Tenon Medical Inc, and EMvision Medical Devices Ltd.
EMvision Medical Devices Ltd is a medical device company that develops, manufactures, and markets non-invasive brain scanning devices. The company’s products include the EMvision Neuro-Monitor, which is used for the detection and monitoring of seizures, and the EMvision Glioma Scanner, which is used for the diagnosis and treatment of brain tumors. The company was founded in 2006 and is headquartered in Sydney, Australia.
TREACE MEDICAL CONCEPTS released their financial results for second quarter of 2023, showing a 40% increase in revenue compared to the same period in the previous year. Net income was reported as -12.3 million, which is an improvement from the -17.2 million reported the year before. Investors may take this as a sign that the company is making strides towards profitability, which could be a positive indicator of long-term potential. However, investors should continue to monitor TREACE’s financial performance and evaluate the risk-reward ratio before committing any capital.